"In an unprecedented surge, India has recorded the highest number of single-day recoveries. More than 1 lakh (101,468) new recoveries have been registered in the last 24 hours in the country," the ministry said in a statement.
"In another landmark achievement, the trend of very high number of single-day recoveries has sustained for the past four consecutive days."
The ministry also said the "total number of recoveries are nearly 45 lakh".
"With this, the total number of recoveries are nearly 45 lakh (4,497,867). This has resulted in the recovery rate touching 80.86 per cent," the ministry said. "79 per cent of the new recovered cases are being reported from ten states, i.e., Maharashtra, Karnataka, Andhra Pradesh, Uttar Pradesh and Tamil Nadu, Odisha, Delhi, Kerala, West Bengal and Punjab."
The ministry said Maharashtra continues to lead with more than 31.5 percent of new recovered patients.
"The continuous streak of very high level of recoveries in the country is a testimony of the Centre-led proactive and graded strategy of -- test, track and treat. The effective clinical management and treatment protocols issued by the federal government have been updated from time to time with the emergence of new medical and scientific evidence," the ministry said.
According to ministry, India's low case fatality rate (CFR) currently stands at 1.59 percent.
Despite that, india, which has a population of more than 1.3 billion, is the world's second worst affected country by Covid-19 behind the United States.
For weeks, it has reported the world's highest daily jump in infections, which reached a total of 5.6 million on Tuesday.
Meanwhile, Reuters reported Dr Reddy's Laboratories Ltd could begin late-stage indian clinical trials of Russia's potential coronavirus vaccine in the next few weeks, an executive at the indian drugmaker said on Tuesday.
indian trials of the Sputnik-V vaccine candidate, being developed by Russia's sovereign wealth fund, will enroll 1,000-2,000 participants and be conducted at multiple government and private hospitals across the country, Deepak Sapra, CEO for API and pharmaceutical services at Dr. Reddy's, told Reuters.
"We want to get to the first step - which is the commencement of the clinical trials by getting the necessary approvals from the indian regulators - within the next few weeks," Sapra said.
The trials are part of a deal between the Russian Direct Investment Fund (RDIF) and Dr Reddy's, in which the indian firm will conduct Phase III studies in india, pursue local regulatory approvals and, subject to approval, distribute the finished vaccine product in india. RDIF will supply 100 million doses to Dr Reddy's.
The RDIF has also reached agreements with indian manufacturers to produce 300 million doses of the shot in india. Russia was the first country to grant regulatory approval for a novel coronavirus vaccine.
Sputnik-V doses supplied in india will likely be a combination of indian- and Russian-made doses, Sapra said, adding that RDIF and Dr Reddy's would soon identify potential manufacturers in india.
The RDIF has said vaccine deliveries to india could begin in late 2020, but Sapra suggested it could take longer. "I think it's going to be several months before we accomplish all the steps in the process," he added.